| Not Yet Recruiting | BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Brea NCT07492641 | BeOne Medicines | Phase 3 |
| Not Yet Recruiting | Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Gen NCT07106632 | UNICANCER | Phase 3 |
| Not Yet Recruiting | Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/ NCT07242352 | West German Study Group | Phase 3 |
| Not Yet Recruiting | Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer NCT07254858 | First Affiliated Hospital of Wenzhou Medical University | Phase 2 |
| Recruiting | Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer NCT06774027 | University of California, San Francisco | — |
| Recruiting | QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer NCT06967103 | Henan Cancer Hospital | Phase 2 |
| Not Yet Recruiting | Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and NCT07005882 | Azienda Ospedaliero-Universitaria Careggi | Phase 2 |
| Recruiting | ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Adv NCT06998407 | Avenzo Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH NCT06874933 | First Affiliated Hospital of Zhejiang University | Phase 2 |
| Recruiting | Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer NCT06860529 | Henan Cancer Hospital | Phase 2 |
| Recruiting | A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors NCT07029399 | NiKang Therapeutics, Inc. | Phase 1 |
| Recruiting | Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-labe NCT06977893 | First Affiliated Hospital of Zhejiang University | Phase 3 |
| Active Not Recruiting | Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for NCT07130643 | Xinhong Wu, PhD | Phase 2 |
| Not Yet Recruiting | Neoadjuvant Chemotherapy + PD-1 Inhibitor+Different Radiotherapy Fractionations for HR+/HER2- Breast Cancer NCT06639672 | Lei Liu | Phase 2 |
| Active Not Recruiting | Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer NCT06599216 | Harbin Medical University | Phase 2 |
| Not Yet Recruiting | To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR NCT06470633 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Recruiting | Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01) NCT06611813 | First Affiliated Hospital of Zhejiang University | Phase 2 |
| Not Yet Recruiting | QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer NCT06404463 | Fudan University | Phase 2 |
| Active Not Recruiting | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advan NCT06343948 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer NCT06447623 | Fudan University | Phase 3 |
| Recruiting | Study of AVZO-021 in Patients With Advanced Solid Tumors NCT05867251 | Avenzo Therapeutics, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Bre NCT05889871 | Fudan University | Phase 3 |
| Recruiting | Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advan NCT06805812 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Unknown | Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer NCT05633914 | Hunan Cancer Hospital | Phase 2 |
| Completed | Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia NCT05789771 | Blokhin's Russian Cancer Research Center | — |
| Recruiting | A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer NCT04282031 | Beta Pharma (Suzhou) Co., Ltd. | Phase 1 / Phase 2 |
| Completed | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer T NCT02983045 | Nektar Therapeutics | Phase 1 / Phase 2 |